KR20230118887A - 유전자 조작 세포 및 이의 용도 - Google Patents
유전자 조작 세포 및 이의 용도 Download PDFInfo
- Publication number
- KR20230118887A KR20230118887A KR1020237022356A KR20237022356A KR20230118887A KR 20230118887 A KR20230118887 A KR 20230118887A KR 1020237022356 A KR1020237022356 A KR 1020237022356A KR 20237022356 A KR20237022356 A KR 20237022356A KR 20230118887 A KR20230118887 A KR 20230118887A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- cells
- cell
- amino acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4234—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Gynecology & Obstetrics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120948P | 2020-12-03 | 2020-12-03 | |
| US202063120799P | 2020-12-03 | 2020-12-03 | |
| US202063120980P | 2020-12-03 | 2020-12-03 | |
| US63/120,799 | 2020-12-03 | ||
| US63/120,948 | 2020-12-03 | ||
| US63/120,980 | 2020-12-03 | ||
| PCT/US2021/072646 WO2022120334A1 (en) | 2020-12-03 | 2021-12-01 | Genetically engineered cells and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230118887A true KR20230118887A (ko) | 2023-08-14 |
Family
ID=79927264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237022356A Pending KR20230118887A (ko) | 2020-12-03 | 2021-12-01 | 유전자 조작 세포 및 이의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12269888B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4255922A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023553419A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230118887A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021392032A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3201621A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL303269A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023006395A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202237827A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022120334A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3210702A1 (en) * | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Gene transfer vectors and methods of engineering cells |
| IL314801A (en) | 2022-02-22 | 2024-10-01 | Juno Therapeutics Inc | Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses |
| CN119630695A (zh) | 2022-06-08 | 2025-03-14 | 世纪治疗股份有限公司 | 表达cd16变体和nkg2d的遗传工程化细胞及其用途 |
| EP4536814A1 (en) * | 2022-06-08 | 2025-04-16 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
| CN120435498A (zh) | 2022-11-10 | 2025-08-05 | 世纪治疗股份有限公司 | 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途 |
| JPWO2025094915A1 (cg-RX-API-DMAC10.html) * | 2023-10-30 | 2025-05-08 | ||
| WO2025101938A2 (en) | 2023-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof |
| WO2025106626A1 (en) | 2023-11-15 | 2025-05-22 | Century Therapeutics, Inc. | Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof |
| WO2025193581A1 (en) * | 2024-03-11 | 2025-09-18 | Musc Foundation For Research Development | Genetically encoded safety switch for transplanted stem cell-derived cells |
| WO2025233825A1 (en) * | 2024-05-06 | 2025-11-13 | Janssen Pharmaceutica Nv | Enrichment of cells expressing a bird linker |
Family Cites Families (275)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| WO1995027722A1 (en) | 1994-04-06 | 1995-10-19 | Immunex Corporation | Interleukin-15 |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| MXPA03002278A (es) | 2000-09-14 | 2004-12-03 | Beth Israel Hospital | Modulacion de respuestas de la celula t mediadas por il-2 e il-15. |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040225112A1 (en) | 2003-05-06 | 2004-11-11 | Crew Mark D. | Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| ES2678094T3 (es) | 2004-07-10 | 2018-08-08 | Fox Chase Cancer Center | Líneas de células asesinas naturales genéticamente modificadas |
| US20060046294A1 (en) | 2004-08-26 | 2006-03-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Site-specific recombination systems for use in eukaryotic cells |
| PT1809321E (pt) | 2004-10-08 | 2012-05-17 | Us Gov Health & Human Serv | Imunoterapia adotiva com sobrevivência aumentada de linfócitos |
| US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| JP5057967B2 (ja) | 2005-03-31 | 2012-10-24 | 中外製薬株式会社 | sc(Fv)2構造異性体 |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US8846395B2 (en) | 2005-06-01 | 2014-09-30 | Wisconsin Alumni Research Foundation | Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| ES2367322T3 (es) | 2005-12-16 | 2011-11-02 | Ribovax Biotechnologies Sa | Métodos para obtener células inmortalizadas que secretan anticuerpos. |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| EP2123754B1 (en) | 2007-01-30 | 2011-04-06 | Forerunner Pharma Research Co., Ltd. | CHIMERIC Fc GAMMA RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| KR100902340B1 (ko) | 2007-08-02 | 2009-06-12 | 한국생명공학연구원 | Yc-1 또는 il-21을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법 |
| US8530636B2 (en) | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
| ES2587395T3 (es) | 2008-06-04 | 2016-10-24 | Cellular Dynamics International, Inc. | Procedimientos para la producción de células IPS usando un enfoque no vírico |
| WO2009152529A2 (en) | 2008-06-13 | 2009-12-17 | Whitehead Institute For Biomedical Research Nine Cambridge Center | Programming and reprogramming of cells |
| JP5652783B2 (ja) | 2008-09-08 | 2015-01-14 | 独立行政法人理化学研究所 | NKT細胞由来iPS細胞およびそれ由来のNKT細胞 |
| US8772028B2 (en) | 2008-11-07 | 2014-07-08 | Sunnybrook Health Sciences Centre | CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using |
| CA2753679C (en) | 2009-02-27 | 2021-03-02 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
| WO2010107658A2 (en) | 2009-03-16 | 2010-09-23 | Vallera Daniel A | Methods and compositions for bi-specific targeting of cd19/cd22 |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープCity of Hope | 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt) |
| JP5950824B2 (ja) | 2009-12-07 | 2016-07-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗腫瘍抗体療法を増強するための方法 |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| US9206394B2 (en) | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
| EP2601289B1 (en) | 2010-08-04 | 2017-07-12 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体il−15可溶性融合分子並びにその製造及び使用方法 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012109208A2 (en) | 2011-02-08 | 2012-08-16 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| DK2699593T4 (da) | 2011-04-20 | 2021-02-08 | Univ Washington Through Its Center For Commercialization | Beta-2 mikroglobulin-deficiente celler |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗cd22キメラ抗原受容体 |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| US9192664B2 (en) | 2011-12-05 | 2015-11-24 | Immunomedics, Inc. | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
| WO2013113615A1 (en) | 2012-02-03 | 2013-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| EP4253409A3 (en) | 2012-04-17 | 2023-12-06 | University of Washington through its Center for Commercialization | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| PL4019041T3 (pl) | 2012-07-13 | 2023-05-08 | The Trustees Of The University Of Pennsylvania | Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| CN104822705B (zh) | 2012-10-24 | 2019-07-12 | 美国卫生和人力服务部 | M971嵌合抗原受体 |
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| AU2014386824B2 (en) | 2013-03-15 | 2019-05-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| DK2986635T3 (en) | 2013-04-18 | 2019-01-28 | Fond Telethon | EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS |
| CA2911946A1 (en) | 2013-05-10 | 2014-11-13 | Numab Ag | Bispecific constructs and their use in the treatment of various diseases |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法 |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| CN105555801B (zh) | 2013-09-18 | 2020-05-05 | 东曹株式会社 | Fc结合性蛋白质、该蛋白质的制造方法和使用了该蛋白质的抗体吸附剂、以及使用了该吸附剂的抗体的纯化方法及识别方法 |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
| CN107074957B (zh) | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| DK3105317T3 (en) | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| RU2752933C2 (ru) | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| CN113699159A (zh) | 2014-03-28 | 2021-11-26 | 明尼苏达大学评议会 | 涉及经工程改造的cd16的多肽、细胞和方法 |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| US11041021B2 (en) | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
| AU2015290554A1 (en) | 2014-07-18 | 2017-03-09 | Kyoto University | Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells |
| MX386342B (es) | 2014-07-25 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Móleculas de unión a her2 y cd3 biespecíficas. |
| TWI542139B (zh) | 2014-07-31 | 2016-07-11 | 瑞昱半導體股份有限公司 | 數位預失真電路與方法以及數位預失真訓練電路 |
| ES2738705T3 (es) | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| WO2016071758A1 (en) | 2014-11-03 | 2016-05-12 | Leiden University Medical Center | T cell receptors directed against bob1 and uses thereof |
| US10813952B2 (en) | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| CN107208079B (zh) | 2014-12-05 | 2021-06-29 | 应用干细胞有限公司 | 整合转基因的位点定向crispr/重组酶组合物和方法 |
| WO2016100236A2 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| US9765330B1 (en) | 2015-01-09 | 2017-09-19 | Nant Holdings Ip, Llc | Compositions and methods for reduction of allograft recognition and rejection |
| WO2016141480A1 (en) | 2015-03-09 | 2016-09-15 | Mount Sinai Hospital | Tools and methods for using cell division loci to control proliferation of cells |
| WO2016149578A1 (en) | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-cd22-anti-cd19 chimeric antigen receptors |
| CN114533867A (zh) | 2015-03-27 | 2022-05-27 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| CN107849102B (zh) | 2015-05-15 | 2022-05-13 | 希望之城 | 嵌合抗原受体组合物 |
| CN108137669B (zh) | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| CA3172801A1 (en) | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| JP6403277B2 (ja) | 2015-06-30 | 2018-10-10 | オートモーティブエナジーサプライ株式会社 | リチウムイオン二次電池の製造方法 |
| JP7033453B2 (ja) | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法 |
| US10493139B2 (en) | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| EP3828266B1 (en) | 2015-07-29 | 2022-11-23 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| CA2994746A1 (en) | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| IL258491B2 (en) | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| WO2017070333A1 (en) | 2015-10-20 | 2017-04-27 | Cellular Dynamics International, Inc. | Multi-lineage hematopoietic precursor cell production by genetic programming |
| WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
| US12642852B1 (en) | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| CA3005753A1 (en) | 2015-11-19 | 2017-06-29 | Bloodcenter Research Foundation | Method of manufacturing dual-specific t-cells for use in cancer immunotherapy |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| AU2016374497B2 (en) | 2015-12-16 | 2022-03-10 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced SH2 protein in NK cells |
| AU2016374253B2 (en) | 2015-12-18 | 2021-10-21 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
| WO2017123559A2 (en) | 2016-01-11 | 2017-07-20 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric proteins and methods of regulating gene expression |
| MX2018010484A (es) | 2016-03-04 | 2019-01-10 | Editas Medicine Inc | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. |
| JP6592184B2 (ja) | 2016-03-24 | 2019-10-16 | 富士フイルム株式会社 | 画像処理装置、画像処理方法、及び画像処理プログラム |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| AU2017248259A1 (en) | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
| LT3444334T (lt) | 2016-04-15 | 2021-12-10 | Kyoto University | Antigenui specifinių cd8 teigiamų t ląstelių indikavimo būdas |
| KR102614675B1 (ko) | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| WO2017190100A1 (en) | 2016-04-28 | 2017-11-02 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| EP3478722A1 (en) | 2016-06-30 | 2019-05-08 | F. Hoffmann-La Roche AG | Improved adoptive t-cell therapy |
| EP3344263A4 (en) | 2016-08-04 | 2020-07-01 | Memorial Sloan-Kettering Cancer Center | CANCER ANTIGEN TARGETS AND USES THEREOF |
| CA3034093A1 (en) | 2016-08-23 | 2018-03-01 | The Regents Of The University Of California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| CN118546961A (zh) | 2016-08-26 | 2024-08-27 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| JP7215994B2 (ja) | 2016-09-06 | 2023-01-31 | ザ チルドレンズ メディカル センター コーポレーション | 人工多能性幹細胞由来の免疫細胞 |
| KR102397771B1 (ko) | 2016-09-23 | 2022-05-13 | 프레드 헛친슨 켄서 리서치 센터 | 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도 |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| IL265953B2 (en) | 2016-10-19 | 2026-05-01 | Cellectis Sa | Gene insertion designed to target for enhanced immune cell therapy |
| JP7231158B2 (ja) | 2016-10-19 | 2023-03-01 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | Cd133結合剤およびその使用 |
| GB201619876D0 (en) | 2016-11-24 | 2017-01-11 | Cambridge Entpr Ltd | Controllable transcription |
| US11427633B2 (en) | 2016-12-13 | 2022-08-30 | Crage Medical Co., Limited | Anti-CD19 humanized antibody and immune effector cell targeting cd 19 |
| US20200087681A1 (en) | 2016-12-21 | 2020-03-19 | Ucl Business Plc | Therapeutic cells |
| WO2018126074A1 (en) | 2016-12-30 | 2018-07-05 | Celularity, Inc. | Genetically modified natural killer cells |
| WO2018127585A1 (en) | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
| KR20240095477A (ko) | 2017-01-13 | 2024-06-25 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 면역조작된 만능 세포 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2018161038A1 (en) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il12 compositions and methods for immunotherapy |
| WO2018165913A1 (zh) | 2017-03-15 | 2018-09-20 | 南京凯地生物科技有限公司 | 靶向nkg2dl的特异性嵌合抗原受体及其car-t细胞以及它们的应用 |
| CN108624608B (zh) | 2017-03-17 | 2021-11-16 | 上海恒润达生生物科技股份有限公司 | 靶向mesothelin的第四代嵌合抗原受体的制备方法和用途 |
| EP3601528A4 (en) | 2017-03-20 | 2021-05-05 | Washington University | Cells and methods of uses and making the same |
| CN110869046B (zh) | 2017-03-31 | 2025-02-25 | 塞勒克提斯公司 | 通用型抗cd22嵌合抗原受体工程化的免疫细胞 |
| US10934336B2 (en) | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| AU2018269194B2 (en) | 2017-05-15 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| EP3635099A4 (en) | 2017-06-07 | 2021-02-24 | The General Hospital Corporation | T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR |
| EP3635132A4 (en) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| CN111511906A (zh) | 2017-06-23 | 2020-08-07 | 因思科瑞普特公司 | 核酸引导性核酸酶 |
| TW201908335A (zh) | 2017-07-25 | 2019-03-01 | 美國德州系統大學評議委員會 | 增強之嵌合抗原受體及其用途 |
| JP2020530997A (ja) | 2017-08-08 | 2020-11-05 | サンガモ セラピューティクス, インコーポレイテッド | キメラ抗原受容体媒介性細胞標的化 |
| EP3441461A1 (en) | 2017-08-11 | 2019-02-13 | Baylor College of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
| EP3684816B1 (en) | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
| US20190091310A1 (en) | 2017-09-26 | 2019-03-28 | Stephen E. Wright | Nonreleased il-12 for therapy of cancer |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| EP3692057B9 (en) | 2017-10-03 | 2023-10-04 | Precision BioSciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| CN107723275B (zh) | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| US11639496B2 (en) | 2017-12-05 | 2023-05-02 | Celyad S.A. | Reducing fratricide of immune cells expressing NKG2D-based receptors |
| CN111556892A (zh) | 2017-12-08 | 2020-08-18 | 菲特治疗公司 | 使用增强的iPSC衍生的效应细胞的免疫疗法 |
| AU2018383712B2 (en) | 2017-12-11 | 2025-09-04 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| CA3082204A1 (en) | 2017-12-13 | 2019-06-20 | Janssen Biotech, Inc. | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
| MA51428A (fr) | 2017-12-22 | 2020-11-04 | Bluebird Bio Inc | Récepteur d'antigène chimérique multivalent |
| BR112020011017A2 (pt) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| AU2019216269B2 (en) | 2018-01-30 | 2025-05-01 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen |
| SG11202007622SA (en) | 2018-02-11 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CA3091158A1 (en) | 2018-02-14 | 2019-08-22 | Sunnybrook Research Institute | Method for generating cells of the t cell lineage |
| CA3090793C (en) | 2018-02-16 | 2024-10-08 | Kite Pharma, Inc. | MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE |
| BR112020018049A2 (pt) | 2018-03-07 | 2020-12-29 | Poseida Therapeutics, Inc. | Composições de cartirina e métodos para uso |
| CN110324069B (zh) | 2018-03-28 | 2021-02-02 | 维沃移动通信有限公司 | 波束失败处理方法、终端、网络设备及可读存储介质 |
| AU2019243315A1 (en) | 2018-03-29 | 2020-09-24 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| WO2019192526A1 (zh) | 2018-04-04 | 2019-10-10 | 达仁生物科技有限公司 | 嵌合抗原受体和其治疗癌症的方法 |
| EP3781704A4 (en) | 2018-04-18 | 2021-12-15 | Altius Institute For Biomedical Sciences | METHOD OF EVALUATING THE SPECIFICITY OF CELL MANIPULATION TOOLS |
| WO2019204643A2 (en) | 2018-04-18 | 2019-10-24 | Altius Institute For Biomedical Sciences | Animal pathogen-derived polypeptides and uses thereof for genetic engineering |
| EP3561053A1 (en) | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| CN108531458A (zh) | 2018-04-27 | 2018-09-14 | 赛诺(深圳)生物医药研究有限公司 | 治疗肿瘤的基因工程自然杀伤细胞产品 |
| SG11202010763VA (en) | 2018-05-03 | 2020-11-27 | Univ Texas | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| CN112839666A (zh) | 2018-05-14 | 2021-05-25 | 因达普塔治疗公司 | 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群 |
| WO2019220109A1 (en) | 2018-05-15 | 2019-11-21 | Autolus Limited | Chimeric antigen receptor |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| IL321548A (en) | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| JP2021525518A (ja) | 2018-05-31 | 2021-09-27 | ワシントン・ユニバーシティWashington University | 細胞をゲノム編集及び活性化するための方法 |
| CN112533942A (zh) | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
| JP2021526860A (ja) | 2018-06-08 | 2021-10-11 | ロックアネイビオ, インコーポレイテッド | 適応免疫をモジュレートするための組成物および方法 |
| CA3103610A1 (en) | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
| WO2019241688A1 (en) | 2018-06-14 | 2019-12-19 | Bluebird Bio, Inc. | Cd79b chimeric antigen receptors |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| EP3810756A4 (en) | 2018-06-25 | 2022-03-23 | Peter MacCallum Cancer Institute | MODIFIED T-CELLS AND USES THEREOF |
| WO2020006126A1 (en) | 2018-06-27 | 2020-01-02 | Altius Institute For Biomedical Sciences | Nucleic acid binding domains and methods of use thereof |
| US12036242B2 (en) | 2018-07-05 | 2024-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T cells that target B-cell antigens |
| JP7072715B2 (ja) | 2018-07-20 | 2022-05-20 | サーフィス オンコロジー インコーポレイテッド | 抗cd112r組成物及び方法 |
| WO2020022512A1 (ja) | 2018-07-26 | 2020-01-30 | 国立大学法人京都大学 | 外来抗原レセプター遺伝子導入細胞の製造方法 |
| CN110305847B (zh) | 2018-07-27 | 2021-05-18 | 赛诺生(深圳)基因产业发展有限公司 | 一种用于治疗肿瘤的基因工程细胞 |
| KR102907902B1 (ko) | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| WO2020060593A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
| US12454574B2 (en) | 2018-10-30 | 2025-10-28 | Board Of Regents, The University Of Texas System | Anti-CD79B antibodies and chimeric antigen receptors and methods of use thereof |
| KR20240162586A (ko) | 2018-10-31 | 2024-11-15 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거 |
| EP4578507A3 (en) * | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| EP3743513A4 (en) | 2018-11-06 | 2021-11-24 | Nantkwest, Inc. | NK-92 CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR |
| US12466892B2 (en) | 2018-11-08 | 2025-11-11 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| AU2019388876A1 (en) | 2018-11-26 | 2021-05-20 | Immunitybio, Inc. | IL-2 Dependent NK-92 cells with stable Fc receptor expression |
| JP7649239B2 (ja) | 2018-11-30 | 2025-03-19 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | キメラ抗原受容体ファクトリおよびその使用方法 |
| JP2022510207A (ja) | 2018-12-02 | 2022-01-26 | フェイト セラピューティクス,インコーポレイテッド | 増強されたiPSC派生エフェクター細胞を使用した免疫療法 |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| WO2020124021A1 (en) | 2018-12-13 | 2020-06-18 | The General Hospital Corporation | Chimeric antigen receptors targeting cd79b and cd19 |
| CN111355871A (zh) | 2018-12-21 | 2020-06-30 | 三赢科技(深圳)有限公司 | 镜头模组及其组装方法 |
| EP3911371A4 (en) | 2019-01-18 | 2023-04-26 | University of Southern California | METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY |
| BR112021016046A2 (pt) | 2019-02-15 | 2021-11-09 | Editas Medicine Inc | Células assassinas naturais modificadas (nk) para imunoterapia |
| CA3130489A1 (en) | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CN113906133A (zh) * | 2019-04-11 | 2022-01-07 | 菲特治疗公司 | 工程改造的iPSC和免疫效应细胞中的CD3重建 |
| BR112021017046A2 (pt) | 2019-04-12 | 2021-11-09 | Phanes Therapeutics Inc | Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos |
| WO2020212756A2 (en) | 2019-04-18 | 2020-10-22 | Genkin Dmitry Dmitrievich | Reprogramming of polymorphonuclear leukocytes |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| US20220213434A1 (en) | 2019-05-10 | 2022-07-07 | The Regents Of The University Of California | Modified pluripotent cells |
| JP7686574B2 (ja) | 2019-05-22 | 2025-06-02 | マサチューセッツ インスティテュート オブ テクノロジー | 環状rna組成物及び方法 |
| CN114174325A (zh) | 2019-06-04 | 2022-03-11 | 恩卡尔塔公司 | 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 |
| AU2020307667A1 (en) | 2019-06-27 | 2022-01-20 | Crispr Therapeutics Ag | Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer |
| WO2021015997A1 (en) | 2019-07-15 | 2021-01-28 | President And Fellows Of Harvard College | Methods and compositions for gene delivery |
| EP4003407A1 (en) | 2019-07-23 | 2022-06-01 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| JP7728747B2 (ja) | 2019-08-23 | 2025-08-25 | サナ バイオテクノロジー,インコーポレイテッド | Cd24発現細胞およびそれらの用途 |
| PH12022550548A1 (en) | 2019-09-06 | 2023-11-20 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
| AU2020364959B2 (en) | 2019-10-07 | 2026-07-09 | Centre National De La Recherche Scientifique - Cnrs - | Antibodies having specificity for Nectin-4 and uses thereof |
| EP4045648A4 (en) | 2019-10-15 | 2023-11-22 | The Regents of The University of California | Transplanted cell protection via fc sequestration |
| EP4045539A4 (en) | 2019-10-17 | 2024-03-13 | Fate Therapeutics, Inc. | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| WO2021081133A1 (en) | 2019-10-21 | 2021-04-29 | Purdue Research Foundation | Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques |
| CN114867485A (zh) | 2019-10-31 | 2022-08-05 | 全国儿童医院研究所 | Cd38敲除的原代和扩增的人nk细胞的生成 |
| WO2021092252A1 (en) | 2019-11-05 | 2021-05-14 | Forman Stephen J | Generation of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereof |
| WO2021095012A1 (en) | 2019-11-13 | 2021-05-20 | Crispr Therapeutics Ag | Methods of manufacturing car-t cells |
| BR112022009290A2 (pt) | 2019-11-13 | 2022-08-09 | Crispr Therapeutics Ag | Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 |
| MX2022005983A (es) | 2019-11-18 | 2022-09-07 | Janssen Biotech Inc | Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos. |
| MX2022006854A (es) | 2019-12-04 | 2022-11-30 | Orna Therapeutics Inc | Composiciones y metodos de arn circular. |
| CN114929250A (zh) | 2019-12-18 | 2022-08-19 | 爱迪塔斯医药公司 | 用于疗法的经工程化的细胞 |
| EP4090747A1 (en) | 2020-01-17 | 2022-11-23 | Sana Biotechnology, Inc. | Safety switches for regulation of gene expression |
| JP2023511965A (ja) | 2020-01-23 | 2023-03-23 | カンステム バイオテック カンパニー リミテッド | Off-the-shelf幹細胞および免疫細胞、それを含む薬学的組成物 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021154218A1 (en) | 2020-01-28 | 2021-08-05 | Nantkwest, Inc. | Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors |
| CA3182286A1 (en) | 2020-05-04 | 2021-11-11 | Editas Medicine, Inc. | Selection by essential-gene knock-in |
| WO2021234662A1 (en) | 2020-05-21 | 2021-11-25 | Crispr Therapeutics Ag | Genetically engineered car t cells that secrete interleukin-12 and therapeutic uses thereof |
| MX2022015586A (es) | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| KR20230040337A (ko) | 2020-06-19 | 2023-03-22 | 페이트 세러퓨틱스, 인코포레이티드 | 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합 |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| WO2022038158A1 (en) | 2020-08-17 | 2022-02-24 | Bicycletx Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
| EP4225373A4 (en) | 2020-10-07 | 2025-01-08 | Dren Bio, Inc. | ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF |
| IL301983A (en) | 2020-10-09 | 2023-06-01 | Fate Therapeutics Inc | Transgenic induced pluripotent stem cells and effector carrier cells of the immune system |
| WO2022087453A1 (en) | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
| WO2022093825A1 (en) | 2020-10-26 | 2022-05-05 | Memorial Sloan-Kettering Cancer Center | Cells with cd70 knockout and uses for immunotherapy |
| WO2022099297A1 (en) | 2020-11-04 | 2022-05-12 | Fate Therapeutics, Inc. | Multiplexed engineered ipsc and immune effector cells targeting solid tumors |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AR124223A1 (es) | 2020-12-03 | 2023-03-01 | Century Therapeutics Inc | Células genéticamente diseñadas y usos de las mismas |
| CN116981685A (zh) | 2020-12-03 | 2023-10-31 | 世纪治疗股份有限公司 | 基因工程化细胞及其用途 |
| AU2022253223A1 (en) | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof |
| AU2022252997A1 (en) | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
| CA3214473A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
-
2021
- 2021-12-01 IL IL303269A patent/IL303269A/en unknown
- 2021-12-01 MX MX2023006395A patent/MX2023006395A/es unknown
- 2021-12-01 CA CA3201621A patent/CA3201621A1/en active Pending
- 2021-12-01 WO PCT/US2021/072646 patent/WO2022120334A1/en not_active Ceased
- 2021-12-01 EP EP21844163.2A patent/EP4255922A1/en active Pending
- 2021-12-01 TW TW110144756A patent/TW202237827A/zh unknown
- 2021-12-01 KR KR1020237022356A patent/KR20230118887A/ko active Pending
- 2021-12-01 AU AU2021392032A patent/AU2021392032A1/en active Pending
- 2021-12-01 JP JP2023534338A patent/JP2023553419A/ja active Pending
-
2023
- 2023-03-30 US US18/193,030 patent/US12269888B2/en active Active
-
2024
- 2024-11-04 US US18/936,773 patent/US20250059286A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230382999A1 (en) | 2023-11-30 |
| IL303269A (en) | 2023-07-01 |
| JP2023553419A (ja) | 2023-12-21 |
| US20250059286A1 (en) | 2025-02-20 |
| MX2023006395A (es) | 2023-06-15 |
| US12269888B2 (en) | 2025-04-08 |
| CA3201621A1 (en) | 2022-06-09 |
| WO2022120334A1 (en) | 2022-06-09 |
| AU2021392032A1 (en) | 2023-06-22 |
| TW202237827A (zh) | 2022-10-01 |
| EP4255922A1 (en) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202237827A (zh) | 經基因工程改造之細胞及其用途 | |
| KR20230170703A (ko) | 유도 만능 줄기세포로부터 감마-델타 t 세포의 생성을 위한 조성물 및 방법 | |
| US20240139248A1 (en) | Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19 | |
| EP3114147B1 (en) | Chimeric antigen receptor | |
| CN109689686B (zh) | 使用融合蛋白进行t细胞受体重编程的组合物和方法 | |
| JP7748935B2 (ja) | IL13Rα2陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成CAR | |
| TW202305114A (zh) | 用於自經誘導之多能幹細胞產生αβ T細胞的組合物及方法 | |
| US20220332782A1 (en) | Combined Artificial Cell Death/Reporter System Polypeptide for Chimeric Antigen Receptor Cell and Uses Thereof | |
| KR20210029707A (ko) | 재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물 | |
| KR20210020873A (ko) | 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법 | |
| WO2015142314A1 (en) | Compositions and methods for immunotherapy | |
| US20240207318A1 (en) | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies | |
| US20240336698A1 (en) | CD38 Chimeric Co-Stimulating Receptor and Uses Thereof | |
| US20240150472A1 (en) | Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody | |
| JP2024525727A (ja) | 抗体由来の結合ドメインに融合した操作されたt細胞受容体 | |
| EP4305054A1 (en) | Selective stimulation of t cells in solid tumors using oncolytic viral delivery of orthogonal il-2 | |
| JP2023521410A (ja) | 大型のアデノウイルスペイロードの組み込み | |
| US20260021181A1 (en) | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies | |
| US20240374641A1 (en) | Generation of car modifiers for tumor treatment | |
| US20230364238A1 (en) | Methods and Compositions Comprising Orthogonal Cytokine Responsive Immune Cells | |
| KR20250111218A (ko) | 혈액학적 암의 치료에 사용하기 위한 키트 | |
| EA048610B1 (ru) | Антиген-узнающие рецепторы, нацеленные на cd371, и их применение | |
| HK1228422A1 (en) | Chimeric antigen receptor | |
| HK1228422B (en) | Chimeric antigen receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |